A novel, first in class, potent, orally bioavailable, brain-penetrant, 11βHSD1 inhibitor1
• Differentiated mechanism of action: blocking cortisol production in the brain
• Symptomatic and disease modifying effects in vivo1
• Well-tolerated – dosed >100 patients/subjects: acceptable clinical safety, toxicity and PK/PD profile1
• Effective human brain concentrations demonstrated1
• XanADu – phase II clinical study underway, dosing subjects with mild AD dementia in USA, UK, AU
• Planning ongoing for additional clinical indications
• Composition of matter IP coverage ≥ 2031, patents granted in all major markets
• XanADu Alzheimer's trial fully funded following completion of ~A$5.3 million capital raise in November 2017
• A range of additional studies adequately funded following completion of ~$17 million capital raising in May 2018
Just happy they have such a strong cash position, $17m +
ACW Price at posting:
5.0¢ Sentiment: Buy Disclosure: Held
